版本:
中国

BRIEF-Selecta Biosciences obtains license for recombinant immunotoxin lmb-100 from National Cancer Institute

May 2 Selecta Biosciences Inc

* Selecta biosciences obtains license for recombinant immunotoxin lmb-100 from national cancer institute (nci) for pancreatic cancer, mesothelioma and other cancers

* Selecta biosciences inc - under terms of license agreement, nci will receive an upfront payment of $50,000 from selecta

* Selecta biosciences-nci entitled upto $9.25 million for milestones, low single-digit royalties on worldwide annual sales of any resulting commercialized treatment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐